Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib plus PD-1 monoclonal antibody in unresectable hepatocellular carcinoma
ChiCTR2000040036Phase 2Recruiting
- Sponsor
- Tongji Hospital
- Start
- Dec 2020
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of regorafenib and PD-1 Monoclonal Antibody in hepatocellular carcinoma (HCC), sponsored by Tongji Hospital. Primary endpoint: Objective response rate. Started Dec 2020; status: recruiting.
02
Drugs
regorafenibPD-1 Monoclonal Antibody
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2000040036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000040036.